We next compared the anti-RCC cell activity of GNE-477 with other known PI3K-Akt-mTOR inhibitors, including a PI3K inhibitor LY294002 [17], an Akt specific inhibitor perifosine [18] and a mTOR kinase inhibitor AZD2014 [19]. This evidence concerns the gene MTOR and renal cell carcinoma.